Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Sep 15;4(12):1953–1960. doi: 10.1158/1940-6207.CAPR-11-0282

Figure 2.

Figure 2

Expression of p16 is not related to cumulative breast cancer incidence or time to breast cancer for women with AH. Observed and expected events are cumulated after accounting for death as a competing risk and are plotted as a function of follow-up interval and stratified by p16 expression levels. Red line, 0–10% cells staining for p16; blue line, 11+% cells staining for p16; black line, expected breast cancer incidence according to Iowa Surveillance, Epidemiology, and End Results survey.